New therapy to stop the progression of aggressive tissue scarring in the lungs and liver.

  • Research and Development

    New therapy to stop the progression of aggressive tissue scarring in the lungs and liver.

    Posted by Pulmonary Fibrosis News Moderator on April 22, 2018 at 8:04 am

    BerGenBio’s bemcentinib can help stop the progression of aggressive tissue scarring in the lungs and liver, as showen in preclinical-trial research. Bemcentinib combats tissue scarring, or fibrosis, by inhibiting a protein called Axl receptor tyrosine kinase. It is associated with various cancers, and its activity is increased in IPF.

    Read more about it here: “BerGenBio Therapy Reins in Lung and Liver Tissue Scarring, Research Shows”

    Have you heard anything else about this new treatment? What are your thoughts about it?

    replied 6 years, 7 months ago 1 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Log in to reply.

Start of Discussion
0 of 0 replies June 2018
Now

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .